COVID-19 vaccine: Covaxin reported adverse event during Phase 1 trials

Business Today | Nov 21, 2020 at 4:44 PM
  • Bharat Biotech’s much-awaited COVID-19 vaccine Covaxin reported a serious adverse event during the Phase 1 clinical trials in August.
  • Bharat Biotech Chairman and Managing Director Dr Krishna Ella reportedly confirmed that the adverse event took place and was duly reported to the drug regulator Central Drugs Standard Control Organisation (CDSCO).
  • A 35-year-old participant with no co-morbidities was affected by the adverse event during the Phase 1 trials at a site in western India.